Assignee
CRAGE MEDICAL CO LTD
CN·14 granted patents·14 pending applications·8 citations·filing 2015–2024
Top patents by PatentIndex Score
28 records- 0193US11525006B2BCMA-targeting antibody and use thereofCRAGE MEDICAL CO LTD·Filed 2018·Granted Dec 13, 2022·6 cites·24 claims
- 0283US2025230232A1Immunologic effector cell of targeted cld18a2, and preparation method and use thereofCRAGE MEDICAL CO LTD·Filed 2024·Application pending·0 cites
- 0382US11447570B2Binding unit targeting fibroblast activation protein α and application thereofCRAGE MEDICAL CO LTD·Filed 2018·Granted Sep 20, 2022·2 cites·12 claims
- 0479US2024342305A1Antibody against glypican-3 and application thereofCRAGE MEDICAL CO LTD·Filed 2024·Application pending·0 cites
- 0576US2025177544A1Method and composition for treating tumorsCRAGE MEDICAL CO LTD·Filed 2024·Application pending·0 cites
- 0675US12098199B2Immunologic effector cell of targeted CLD18A2, and preparation method and use thereofCRAGE MEDICAL CO LTD·Filed 2021·Granted Sep 24, 2024·0 cites·10 claims
- 0770US2024269175A1Compositions and methods of cellular immunotherapyCRAGE MEDICAL CO LTD·Filed 2023·Application pending·0 cites
- 0867US12186343B2Method and composition for treating tumorsCRAGE MEDICAL CO LTD·Filed 2019·Granted Jan 7, 2025·0 cites·20 claims
- 0967US11596653B2Compositions and methods of cellular immunotherapyCRAGE MEDICAL CO LTD·Filed 2018·Granted Mar 7, 2023·0 cites·29 claims
- 1064US12435119B2Genetically engineered cell and application thereofCRAGE MEDICAL CO LTD·Filed 2019·Granted Oct 7, 2025·0 cites·38 claims
- 1160US12168061B2Antibody against glypican-3 and application thereofCRAGE MEDICAL CO LTD·Filed 2016·Granted Dec 17, 2024·0 cites·26 claims
- 1260US2024181055A1Cellular immunotherapy useCRAGE MEDICAL CO LTD·Filed 2022·Application pending·0 cites
- 1359US11419895B2Compositions and methods of cellular immunotherapyCRAGE MEDICAL CO LTD·Filed 2018·Granted Aug 23, 2022·0 cites·10 claims
- 1458US2024226151A9Cd94 engineered cell and composition thereofCRAGE MEDICAL CO LTD·Filed 2022·Application pending·0 cites
- 1556US2023310600A1Engineered cells and method for engineering cellsCRAGE MEDICAL CO LTD·Filed 2021·Application pending·0 cites
- 1655US2023272341A1Multifunctional immune effector cell and use thereofCRAGE MEDICAL CO LTD·Filed 2021·Application pending·0 cites
- 1754US2022325241A1Immune effector cell for co-expressing chemokine receptorCRAGE MEDICAL CO LTD·Filed 2020·Application pending·0 cites
- 1853US2023148586A1Low-temperature storage of biological samplesCRAGE MEDICAL CO LTD·Filed 2021·Application pending·0 cites
- 1953US2023061005A1Anti-claudin 18.2 antibody and use thereofCRAGE MEDICAL CO LTD·Filed 2021·Application pending·0 cites
- 2053US2023158071A1Tumor combined immunotherapyCRAGE MEDICAL CO LTD·Filed 2019·Application pending·0 cites
- 2152US12534532B2CLL1-targeting antibody and application thereofCRAGE MEDICAL CO LTD·Filed 2019·Granted Jan 27, 2026·0 cites·20 claims
- 2252US2023143947A1Immune effector cell in which expression is regulated by cytokinesCRAGE MEDICAL CO LTD·Filed 2020·Application pending·0 cites
- 2349US2022356447A1Cell for resisting transplant reaction and methodCRAGE MEDICAL CO LTD·Filed 2020·Application pending·0 cites
- 2445US12178786B2Combination of cellular immunotherapyCRAGE MEDICAL CO LTD·Filed 2019·Granted Dec 31, 2024·0 cites·16 claims
- 2545US11299525B2Chimeric antigen receptor-modified immune effector cell carrying PD-L1 blocking agentCRAGE MEDICAL CO LTD·Filed 2016·Granted Apr 12, 2022·0 cites·11 claims
- 2644US11427633B2Anti-CD19 humanized antibody and immune effector cell targeting cd 19CRAGE MEDICAL CO LTD·Filed 2017·Granted Aug 30, 2022·0 cites·28 claims
- 2743US11530270B2Antibody targeting IL-13RA2 and use thereofCRAGE MEDICAL CO LTD·Filed 2018·Granted Dec 20, 2022·0 cites·13 claims
- 2835US11453860B2GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereofCRAGE MEDICAL CO LTD·Filed 2015·Granted Sep 27, 2022·0 cites·11 claims
Join the waitlist — get patent alerts
Get an alert when CRAGE MEDICAL CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →